| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Luciferase enzymes (such as those engineered for coelenterazine substrates) are the primary molecular targets. As a coelenterazine analog, QZ is a substrate for luciferases, and upon oxidation by luciferase, it emits bioluminescent light. This enables detection of luciferase-expressing cells or tissues in vivo.
|
|---|---|
| ln Vitro |
In cell-free assays, QZ serves as a substrate for luciferase enzymes. The bioluminescent signal generated upon luciferase-mediated oxidation exhibits red-shifted emission relative to native coelenterazine. The activity is assessed by mixing QZ with recombinant luciferase in an assay buffer and measuring the emitted light intensity and emission spectrum.
|
| ln Vivo |
There is no specific in vivo activity data available for this compound beyond its use as an imaging agent. QZ is used in animal models to visualize luciferase-expressing cells (e.g., tumors, immune cells) with improved tissue penetration and reduced background due to its red-shifted emission and low autoluminescence.
|
| Enzyme Assay |
A standard protocol involves dissolving QZ in an appropriate solvent (e.g., ethanol or DMSO) to a stock concentration of 10-50 mM and then diluting it in PBS or saline to a working concentration (e.g., 100-500 uM). The diluted substrate is injected intravenously into a luciferase-expressing animal model. The bioluminescence signal is then captured using an in vivo imaging system (IVIS) equipped with appropriate emission filters to capture the red-shifted light. For cell-free assays, mix QZ with recombinant luciferase and measure light output.
|
| Cell Assay |
There is no specific cell-based protocol for QZ, as it is primarily used for in vivo imaging. For in vitro luciferase assays, cells expressing luciferase (e.g., luciferase-transfected cell lines) can be incubated with QZ (e.g., 50-200 uM) in culture medium for 5-30 minutes, and bioluminescence is measured with a plate reader.
|
| Animal Protocol |
A typical in vivo protocol involves intravenous injection of QZ (e.g., 0.1-1 mg per animal, typically 50-200 uL of a 0.5-2 mg/mL solution) into a live animal model expressing luciferase (e.g., tumor-bearing mice). Imaging is performed immediately after injection or at multiple time points (e.g., 5-30 minutes post-injection) using an IVIS system. Red-shifted emission allows for deeper tissue penetration and more accurate signal quantification.
|
| ADME/Pharmacokinetics |
General PK properties for QZ: As a coelenterazine analog, it is rapidly distributed after IV injection and cleared within minutes to hours. The red-shifted emission reduces background autofluorescence from tissues, improving signal-to-noise ratio. Formulation typically in a mixture of water and co-solvents (e.g., ethanol, propylene glycol).
|
| Toxicity/Toxicokinetics |
General toxicity for bioluminescent substrates is considered low at imaging doses. No specific toxicity data is available for QZ. Coelenterazine analogs generally exhibit good biocompatibility with low acute toxicity.
|
| References | |
| Additional Infomation |
QZ is a research tool for bioluminescence imaging (BLI) of luciferase-expressing cells in living animals. Its red-shifted emission (longer wavelength) allows for better tissue penetration and lower background compared to native coelenterazine, making it especially useful for deep-tissue imaging and multiplexed bioluminescence imaging. This product is for research use only.
|
| Molecular Formula |
C28H20N4O
|
|---|---|
| Molecular Weight |
428.48
|
| Exact Mass |
428.163
|
| CAS # |
2883232-39-9
|
| PubChem CID |
164517221
|
| Appearance |
Yellow to orange solid powder
|
| Density |
1.28±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)
|
| Boiling Point |
619.9±65.0 °C(Predicted)
|
| LogP |
6.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
633
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=C(CC2C=CC=CC=2)N=C2C(C3C=CN=C4C=CC=CC=34)=NC(C3C=CC=CC=3)=CN21
|
| InChi Key |
LWNKLLCUKRDPJP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H20N4O/c33-28-24(17-19-9-3-1-4-10-19)31-27-26(22-15-16-29-23-14-8-7-13-21(22)23)30-25(18-32(27)28)20-11-5-2-6-12-20/h1-16,18,33H,17H2
|
| Chemical Name |
2-benzyl-6-phenyl-8-quinolin-4-ylimidazo[1,2-a]pyrazin-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 25 mg/mL (58.35 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3338 mL | 11.6692 mL | 23.3383 mL | |
| 5 mM | 0.4668 mL | 2.3338 mL | 4.6677 mL | |
| 10 mM | 0.2334 mL | 1.1669 mL | 2.3338 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
